Covidien Enters Biologic Tissue Implant Market Via $80 Mil. TSL Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Covidien gains the Permacol biologic tissue repair implant for hernias and other applications through its $80 million purchase of Tissue Science Laboratories, announced March 12